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liver disease, which promotes hepatic
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sylmethionine (SAMe), a natural UBC9-
dependent SUMOylation inhibitor, halted pol-
ycystic liver disease in experimental models,
thus representing a potential therapeutic
agent for patients.
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httpTargeting UBC9-mediated protein hyper-SUMOylation in cystic
cholangiocytes halts polycystic liver disease in experimental models
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disorders characterized by progressive development of multiple
fluid-filled biliary cysts. Most PLD-causative genes participate in
protein biogenesis and/or transport. Post-translational modifi-
cations (PTMs) are implicated in protein stability, localization
and activity, contributing to human pathobiology; however, their
role in PLD is unknown. Herein, we aimed to unveil the role of
protein SUMOylation in PLD and its potential therapeutic
targeting.
Methods: Levels and functional effects of SUMOylation, along
with response to S-adenosylmethionine (SAMe, inhibitor of the
SUMOylation enzyme UBC9) and/or short-hairpin RNAs
(shRNAs) against UBE2I (UBC9), were evaluated in vitro, in vivo
and/or in patients with PLD. SUMOylated proteins were deter-
mined by immunoprecipitation and proteomic analyses by mass
spectrometry.
Results: Most SUMOylation-related genes were found overex-
pressed (mRNA) in polycystic human and rat liver tissue, as well
as in cystic cholangiocytes in culture compared to controls.
Increased SUMOylated protein levels were also observed in
cystic human cholangiocytes in culture, which decreased after
SAMe administration. Chronic treatment of polycystic (PCK:
Pkdh1-mut) rats with SAMe halted hepatic cystogenesis and
fibrosis, and reduced liver/body weight ratio and liver volume.
In vitro, both SAMe and shRNA-mediated UBE2I knockdown
increased apoptosis and reduced cell proliferation of cysticwords: Hepatic cystogenesis; Post-translational modifications; SUMOylation;
enosylmethionine (SAMe); Therapy.
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Journal of Hepatology 2immunoprecipitated proteins in cystic cholangiocytes identified
candidates involved in protein biogenesis, ciliogenesis and
proteasome degradation. Accordingly, SAMe hampered protea-
some hyperactivity in cystic cholangiocytes, leading to activa-
tion of the unfolded protein response and stress-related
apoptosis.
Conclusions: Cystic cholangiocytes exhibit increased SUMOyla-
tion of proteins involved in cell survival and proliferation, thus
promoting hepatic cystogenesis. Inhibition of protein SUMOyla-
tion with SAMe halts PLD, representing a novel therapeutic
strategy.
Lay summary: Protein SUMOylation is a dynamic post-
translational event implicated in numerous cellular processes.
This study revealed dysregulated protein SUMOylation in
polycystic liver disease, which promotes hepatic cystogenesis.
Administration of S-adenosylmethionine (SAMe), a natural UBC9-
dependent SUMOylation inhibitor, halted polycystic liver disease
in experimental models, thus representing a potential therapeutic
agent for patients.
© 2020 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Polycystic liver disease (PLD) is a collection of heterogeneous
genetic disorders marked by the presence of numerous fluid-
filled hepatic cysts (>10) arising from the intrahepatic biliary
epithelia. PLD manifests as either isolated liver cysts in auto-
somal dominant polycystic liver disease (ADPLD) or in conjunc-
tion with renal cysts in autosomal dominant polycystic kidney
disease (ADPKD) and autosomal recessive polycystic kidney
disease (ARPKD).1 Progressive liver cyst growth gives rise to
debilitating symptoms related to organ compression, like dys-
pnea, early satiety and pain in the abdomen and/or back. Com-
plications occur infrequently and consist of cyst hemorrhage,021 vol. 74 j 394–406
infection or rupture in cysts, as well as obstructive jaundice and
portal hypertension. Current therapies include percutaneous (i.e.,
aspiration sclerotherapy), surgical (i.e., liver fenestration, resec-
tion) and pharmacological (i.e., somatostatin analogs) ap-
proaches, which usually show short-term and modest benefits.1
As a corollary, there is high demand for novel therapeutic stra-
tegies, as liver transplantation remains the only curative treat-
ment. Unraveling the molecular mechanisms implicated in the
pathogenesis of PLD aims to fulfill this unmet need.
The majority of PLD-related genes (i.e., PRKCSH, SEC63, PKD2,
GANAB, ALG8, ALG9, and SEC61B) encode for endoplasmic retic-
ulum (ER)-resident proteins involved in the synthesis, matura-
tion, folding and transport of nascent proteins.2 On the other
hand, mutations in the PLD-causative genes PKD1, PKD2 and
PKHD1 directly affect proteins located into the primary cilium of
cholangiocytes, leading to abnormalities in cell polarity and
calcium homeostasis, which compromise multiple cell processes
including protein biogenesis, proliferation, differentiation and
secretion.3 Consequently, these gene mutations provoke global
abnormalities in both cellular protein homeostasis (i.e., proteo-
stasis) and function of the protein products, resulting in ER stress
and the activation of pro-survival mechanisms.4 Taken this
knowledge into account, we hypothesized that cystic chol-
angiocytes might be characterized by abnormal protein dy-
namics linked to adaptive post-translational modification (PTM)
processes, leading to the promotion of hepatic cystogenesis.
Among the different PTMs, protein SUMOylation has drawn
increasing attention as it is an essential and reversible process,
governing a plethora of cellular actions such as gene transcrip-
tion, protein stability, nucleo-cytoplasmic trafficking, cell cycle
regulation, and apoptosis. However, its role in the pathobiology
of biliary diseases, particularly in PLD, is unknown.
Protein SUMOylation involves the covalent and reversible
binding of a small ubiquitin-like modifier (SUMO) to a substrate
acceptor lysine residue. SUMO binding to proteins is regulated
through an enzymatic cascade that involves the heterodimer E1
activating enzyme (SAE1/UBA2), E2 conjugating enzyme (UBC9)
and an E3 ligating enzyme. Three SUMO paralogs (SUMO1-3)
have been identified, SUMO1 being the most ubiquitous conju-
gated form.5 SUMO2 and SUMO3 share a sequence identity of
97%, and are therefore often referred as SUMO2/3. Dysregulated
protein SUMOylation has recently been demonstrated to
contribute to human pathobiology, including liver conditions
such as hepatocellular carcinoma (HCC) and non-alcoholic fatty
liver disease (NAFLD).6–8 Prominently, S-adenosylmethionine
(SAMe), mainly synthesized in the liver in the first reaction of the
methionine cycle by the action of the enzyme methionine ade-
nosyltransferase (MAT) I/III, is a natural inhibitor of UBC9, the
sole E2-conjugating enzyme.6 The present study aims to unveil




Cysticwall tissue frompatientswith PLD (n = 16), aswell as healthy
human gallbladder (n = 14) and liver (n = 14) biopsies were ob-
tained from Radboud University Medical Center (Nijmegen, The
Netherlands) and Donostia University Hospital (San Sebastian,
Spain), respectively. Immunohistochemistry (IHC) was performed
in paraffin-embedded liver tissue from theMayo Clinic (Rochester,
MN, USA), Radboud University Medical Center and DonostiaJournal of Hepatology 2University Hospital. Table S1 summarizes the main demographic
and clinical features of the patients included in the study. Research
protocolswere approved by the Clinical Research Ethics Committees
of supporting Institutions [MSA-MMR-2017-01 (Donostia), 2012/
317 (Radboud) and Mayo Clinic-IRB], and all patients signed writ-
ten consent for the use of their samples for biomedical research.
PLD animal model
The polycystic (PCK) rat (PCK/CrljCrl-Pkhd1pck/Crl; Charles River
Laboratory) carries a spontaneous mutation in the polycystic
kidney and hepatic disease 1 (Pkhd1) orthologous gene,
responsible for an ARPKD/congenital hepatic fibrosis phenotype
characterized by bile duct dilation and progressive development
of intrahepatic biliary cysts (i.e., isolated cysts at 6-months-old)
and hepatic fibrosis.9,10 This animal model is widely used to
study PLD pathobiology, although it has some differences with
ADPLD/ADPKD phenotypes in terms of pathogenesis and
fibrosis.2 8-week-old PCK rats (n = 12) were treated with 20 mg/
kg/day S-adenosyl-l-methionine disulfate p-toluenesulfonate
(SAMe, kindly provided by Gnosis S.p.A., Desio, Italy) for 5
months by oral gavage. SAMe dosage was based on published
studies.11 As non-treated controls, 8-week-old wild-type (WT,
Sprague-Dawley, Charles River Laboratory) (n = 8) and PCK (n =
14) rats were maintained in parallel (Fig. S1). Analysis of serum
biochemical markers, physical parameters, and endpoints of
hepatic cystogenesis and fibrosis are described in the
Supplementary data. All animal experimental procedures were
approved by the Animal Experimentation Ethics Committee of
Biodonostia Health Research Institute (CEEA17/007).
Human and rat cholangiocyte primary cultures
Normal and polycystic human cholangiocytes, NHCs and PHCs
respectively, were isolated as previously described.12 PHCs har-
bor a missense mutation [c.2515C>T, p.(Arg839Trp)] in the
GANAB gene.13 Likewise, normal rat cholangiocytes (NRCs) and
Pkhd1-mut rat cholangiocytes (PCKs) were isolated and
cultured.14 All primary cells were cultured in fully supplemented
DMEM/F-12 medium as previously described.12
RNA isolation, retrotranscription and gene expression
RNA isolation was performed in human and rat liver tissue, as
well as in cell cultures, using TRI Reagent (Sigma). Subsequently,
reverse transcription and quantitative real-time PCRs (qPCRs)
were carried out as described in the Supplementary data.
Expression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) served as normalizing control. Primer sequences (Sigma)
are included in Table S2 and the supplementary CTAT table.
Immunohistochemistry
Detection of SUMO1 protein expression (i.e., free SUMO1 and
SUMO1-conjugated proteins), ubiquitin and p62 by IHC was
carried out on paraffin-embedded sections from normal, ADPKD
and ARPKD human liver tissues, as well as in normal rat and PCK
tissues, as previously described.12 In addition, UBC9 protein
expression was stained in normal and PCK rat liver tissues. The
antibodies used are listed in Table S3 and the CTAT table.
Immunoblotting
Changes in levels of SUMO1, SUMO1-conjugated proteins,
ubiquitin-conjugated proteins, p62 and acetylated a-tubulin
were analyzed by immunoblotting using whole cell lysates or021 vol. 74 j 394–406 395
Research Article Experimental and Translational HepatologySUMO1-immunoprecipitation (IP) cell lysates of cultured human
cholangiocytes, as described in the Supplementary data.
3D cystic growth
Biliary cysts were isolated from PCK rats and cultured as previ-
ously reported.12 Twenty-four hours after isolation, 1.0 mM
SAMe was added daily into the culture medium and the 3D
expansion of cysts was monitored (at 24 h and 48 h) by light
microscopy. The circumferential area of the cystic cholangioids
was assessed using ImageJ software (National Institutes of
Health, USA).
Cell viability, proliferation and apoptosis
Cell viability, proliferation and apoptosis assays in human and rat
cholangiocytes in culture were evaluated in the presence or
absence of different compounds (i.e., SAMe and/or the protea-
some inhibitor MG132 [Sigma]) as described in the
supplementary information.
Primary cilia
The number of ciliated PHCs in the presence or absence of SAMe
in the culture media was analyzed by immunofluorescence, as
described in the supplementary information.
Cell transfection with short-hairpin RNA
PHCs were either transfected with control short-hairpin RNA
(shRNA, Sigma) or shRNA against UBE2I (Sigma) using FuGENE
HD (Promega), or left untransfected as experimental control.
Stable transfected cells were obtained by selecting puromycin
(Sigma) resistant cells, and UBE2I knockdown was verified by
protein expression using immunoblotting. Details are outlined in
the supplementary information.
Immunoprecipitation
Whole cell lysates from NHCs and PHCs were incubated with
Dynabeads Protein G (Invitrogen), which were crosslinked to
SUMO1 or immunoglobulin G (IgG) antibodies (Abcam). The
proteins were eluted from the beads with 2% SDS as described in
the supplementary information.
Mass spectrometry and proteomic analysis
Comparative shotgun proteomic analyses of control-shRNA and
shRNA-UBE2I samples, as well as SUMO1-IP lysates, were per-
formed as described in the supplementary information.
Proteasome activity
Proteasomal degradation of proteins was determined using the
Proteasome-GloTM Cell-Based Assay (Promega, Madison, WI) in
NHCs and PHCs at baseline conditions and after incubation with
1.0 mM SAMe, following manufacturer’s instructions and as
detailed in the supplementary information.
Statistical analysis
Statistical analysis was performed using GraphPad Prism soft-
ware (Version 8.3, San Diego, CA, USA). First, Shapiro-Wilk
normality test was evaluated, and then, parametric Student’s
t tests or non-parametric Mann-Whitney tests were applied to
compare statistical significance between 2 groups. For compari-
sons between more than 2 groups, parametric one-way analysis
of variance (ANOVA) or non-parametric Kruskal-Wallis tests
followed by a posteriori Tukey or Dunns tests were used,396 Journal of Hepatology 2respectively. Data are expressed as means ± SEM, and differences
of p <0.05 were considered statistically significant.
For further details regarding the materials and methods used,
please refer to the CTAT table and supplementary information.
Results
The SUMOylation machinery is upregulated in PLD
To determine whether SUMOylation and genes involved in SAMe
synthesis are altered in PLD, expression (mRNA) levels were
determined in cystic tissue of patients with PLD and compared to
healthy human gallbladder (GB, which is enriched in chol-
angiocytes) and liver tissue. Cystic tissue of patients with PLD
showed higher expression of E2 conjugating enzyme, UBC9
(UBE2I), and E1 activating enzyme subunit 1, SAE1 (SAE1), when
compared to both GB and liver tissues (Fig. 1A). In addition, E1
activating enzyme subunit 2, UBA2 (UBA2), and the substrate
itself, SUMO1 (SUMO1), were overexpressed in cystic tissue
compared to GB tissue (Fig. 1A). On the other hand, the genes
involved in the generation of MAT, which catalyze SAMe syn-
thesis, MAT2A and MAT2B (widely expressed in extrahepatic
tissues), were found overexpressed in PLD when compared to GB
tissue (Fig. 1A). No significant differences were seen in MAT1A
(mainly expressed in liver tissue) or MAT2A-B expression be-
tween PLD and liver tissue, whereas decreased MAT1A expres-
sion was observed in GB compared to liver tissue (Fig. 1A). In
parallel, the expression (mRNA) levels of the key enzymes
involved in SUMOylation and SAMe synthesis were measured in
liver tissue of normal and PCK rats. Similar trends of expression
were seen in liver tissue of PCK compared to WT rats, with
upregulation of Ube2i, Sae1, Uba2, Sumo1 and Mat2a. On the
other hand, the expression of Mat1a was found downregulated,
whereas Mat2b expression remained unchanged, in PCK vs. WT
livers (Fig. 1B). Moreover, immunostaining of the liver showed an
enrichment of SUMO1 (i.e., combination of free SUMO1 ligand
and SUMO1-conjugated proteins) in the cystic epithelium of
patients with ADPKD and ARPKD, as well as in PCK rats,
compared to the biliary epithelium of healthy controls (Fig. 1C).
In particular, SUMO1 overexpression was preferentially found in
the nucleus of cystic cholangiocytes, indicating an upregulation
of SUMO1 conjugation to proteins.
To examine whether SUMOylation and SAMe synthesis were
also dysregulated at the cellular level, the same array of genes
was evaluated in primary cultures of NHCs, PHCs, NRCs and PCK
cholangiocytes. In human cells, upregulation of every gene was
observed in PHCs (Fig. 2A), corroborating the results obtained in
tissue. Comparable alterations were observed in PCK chol-
angiocytes, with the exception of Sae1 and Sumo1. While the
expression of Sae1 is comparable in both normal and cystic rat
cholangiocytes, Sumo1 is downregulated in PCK cholangiocytes
compared to NRCs (Fig. 2B). On the other hand, MAT1A or Mat1a
expression was not detected in either human or rat cell culture
(data not shown). Importantly, the analysis of SUMOylation at
the protein level demonstrated substantially higher levels of
SUMO1 and SUMO1-conjugated proteins in PHCs compared to
NHCs (Fig. 2C). In view of the hyper-SUMOylation state in cystic
cholangiocytes, the effect of SAMe administration, a natural in-
hibitor of UBC9, was further evaluated.6 Incubation of PHC with
SAMe abolished the increased levels of SUMO1-conjugated
proteins in PHCs, restoring the SUMOylation status to similar
levels seen in NHCs (Fig. 2C). On the other hand, the levels of free
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Fig. 1. Expression levels of the SUMOylation and SAMe synthesis pathway components in cystic human and rat tissue. (A) mRNA expression of genes
involved in SUMOylation and SAMe synthesis in healthy [human gallbladder (GB) (n = 14) and liver tissue (n = 14)] and cystic tissue of patients with PLD (n = 16),
as well as (B) in liver tissue of WT (n = 8) and PCK (n = 14) rats. (C) Representative IHC images of SUMO1 and SUMO1-conjugated proteins in human and rat liver
tissue. Scale bars: 500 lm. *p <0.05; **p <0.01; ***p <0.001 (one-way ANOVA tests, Kruskal-Wallis, Mann-Whitney or 2-tailed t tests). IHC, immunohistochemistry;
PCK, polycystic; PLD, polycystic liver disease; SAMe, S-adenosylmethionine; WT, wild-type.SAMe halts hepatic cystogenesis and fibrosis in PCK rats
To further investigate whether modulation of SUMOylation with
SAMe represents a potential therapeutic strategy for patients with
PLD, PCK rats were chronically administered with SAMe (20 mg/
kg/day for 5 months). Administration of SAMe halted hepatic
cystogenesis in PCK rats, reflected by the lower liver weight, liver/
body weight ratio and liver volume, when compared to non-
treated PCK rats (Fig. 3A). In addition, a partial normalization of
the decreased serum albumin levels of PCK rats was evident afterJournal of Hepatology 2SAMe treatment (Fig. 3A). Mitigation of hepatic cystogenesis was
further strengthened by changes seen at macroscopic and
microscopic levels (Fig. 3B). Hepatic cystic and fibrotic areas, as
well as liver cystic volume from PCK rats, were reduced after
SAMe treatment (Fig. 3C). Importantly, SUMO1 (i.e., combination
of free SUMO1 ligand and SUMO1-conjugated proteins) and UBC9
protein overexpression in PCK biliary cysts was lowered after
SAMe treatment (Fig. 3D). On the other hand, SAMe treatment did
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Fig. 2. Expression levels of the SUMOylation and SAMe synthesis pathway components in human and rat cystic cholangiocytes in vitro. (A) mRNA
expression of genes involved in SUMOylation and SAMe synthesis in NHCs (n = 6) and PHCs (n = 6), as well as (B) in NRCs (n = 11) and PCK cholangiocytes (n = 11).
(C) Representative immunoblot and quantification of SUMO1 and SUMO1-conjugated proteins in NHCs and PHCs, in the presence or absence of SAMe (n = 3). *p
<0.05; **p <0.01; ***p <0.001 (one-way ANOVA tests, Kruskal-Wallis, Mann-Whitney or 2-tailed t tests). NHCs, normal human cholangiocytes; NRCs, normal rat
cholangiocytes; PHCs, polycystic human cholangiocytes; PCKs, polycystic rat cholangiocytes; SAMe, S-adenosylmethionine.
Research Article Experimental and Translational Hepatology(i.e., alanine aminotransferase and aspartate aminotransferase
[AST]) and cholestasis (i.e., alkaline phosphatase); the expression
of tissue biomarkers of liver injury (i.e. pro-inflammatory and pro-
fibrotic genes) and SUMOylation genes; or renal cystogenesis
(Fig. S2; Table S4). Finally, 3D cultures of biliary cysts isolated
from PCK rats were incubated in the presence or absence of SAMe
(1.0 mM) and followed up for 3 days. In these conditions, PCK
cystic cholangioids grew overtime (Fig. 3E). Interestingly, the
presence of SAMe (for 48 h) decreased the cystic cholangioid
growth compared to control conditions (Fig. 3E), resembling the
effects observed with SAMe in vivo.
SAMe inhibits cystic growth in vitro by impacting on cell
survival, proliferation and differentiation
To further address the direct effects of SAMe on cystic chol-
angiocytes, cell survival, proliferation and apoptosis assays were
performed. First, cell viability was measured using different
concentrations of SAMe in both human and rat normal and cystic398 Journal of Hepatology 2cholangiocyte cultures. Of note, SAMe decreased cell viability of
both PHCs and PCK cholangiocytes in a dose-dependent manner
when compared to their respective untreated controls (Fig. 4A
and Fig. S3A, respectively); moreover, the effect of SAMe on cell
viability was significantly stronger in cystic cholangiocytes than
in normal cholangiocytes (both human and rat). Since cell
viability is the result of the balance between survival and pro-
liferation, both cellular processes were investigated next. The
exposure of cystic cholangiocytes to SAMe induced a dose-
dependent apoptosis in both PHCs and PCK cholangiocytes
compared to normal controls where SAMe had no or minor effect
(Fig. 4B and Fig. S3B, respectively). A main feature of cystic
cholangiocytes is their baseline hyperproliferation compared to
normal cholangiocytes.2,14 Interestingly, SAMe caused a dose-
dependent reduction of cell proliferation in both PHC and PCK
cholangiocytes (Fig. 4C and Fig. S3C, respectively), which was of
greater magnitude in the latter. Furthermore, incubation of PHCs

































































































































Fig. 3. Effect of SAMe administration on hepatic cystogenesis and fibrosis in PCK rats. (A) Physical parameters and serum albumin levels in WT (n = 8) and
PCK (untreated [n = 14] and SAMe-treated [n = 12]) rats. (B) Representative liver images (scale bar: 1 cm), H&E and picrosirius red staining (scale bar: 500 lm). (C)
Hepatic cystogenesis and fibrosis quantification in PCK (untreated and SAMe-treated) rats. (D) Representative IHC images of SUMO1 and UBC9 in rat liver tissue.
(E) 3D-cultured PCK cysts in the presence/absence of SAMe (n = 12) (T0: time zero). *p <0.05; **p <0.01; ***p <0.001 (one-way ANOVA, Kruskal-Wallis, Mann-
Whitney or 2-tailed t-tests, except fibrosis [one-tailed t test]). IHC, immunohistochemistry; PCK, polycystic; SAMe, S-adenosylmethionine; WT, wild-type.differentiation (SOX9 and SOX17) and cell polarity (ZO-1) markers
(Fig. 4D). Notably, SAMe increased the levels of acetylated
a-tubulin (a primary cilium marker) in PHCs, as well as the
number of ciliated cells (Figs. 4E,F, respectively).Journal of Hepatology 2Experimental knockdown of UBE2I mimics SAMe effects in
cystic cholangiocytes in vitro
As mentioned above, SAMe has been described to regulate
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Fig. 4. Biological impact of SAMe on survival and proliferation of normal and cystic cholangiocytes in culture. Cell (A) viability (n = 6), (B) apoptosis (n = 4)
and (C) proliferation (n = 3) in untreated or SAMe-treated NHCs and PHCs. (D) mRNA levels of epithelial and polarity markers in the presence/absence of SAMe.
(E) Immunoblot and quantification of acetylated a-tubulin in cultured PHCs, in the presence/absence of SAMe (n = 6). (F) Immunofluorescence images of
acetylated a-tubulin in PHCs (primary cilium in green and nucleus in blue) in the presence/absence of SAMe (n = 24) (scale bars: 20 lm, 4 lm [cropped]). *p <0.05;
**p <0.01; ***p <0.001 (one-way ANOVA, Kruskal-Wallis, Mann-Whitney or 2-tailed t-tests). NHCs, normal human cholangiocytes; PHCs, polycystic human
cholangiocytes; SAMe, S-adenosylmethionine.
Research Article Experimental and Translational Hepatologyenzyme in SUMOylation. To validate whether the functional ef-
fects exerted by SAMe were through UBC9 inhibition, stable
shRNA-mediated UBE2I knockdown in PHCs was evaluated.
Immunoblotting confirmed UBE2I silencing, as UBC9 protein
levels were reduced by 65–75% in shRNA-UBE2I compared
shRNA-control or non-transfected cystic cholangiocytes respec-
tively (Fig. 5A). In accordance, shRNA-UBE2I PHCs presented
reduced protein SUMOylation (Fig. 5B). Consistent with SAMe
treatment, UBC9 depletion had pro-apoptotic and anti-400 Journal of Hepatology 2proliferative consequences in PHCs compared to both controls
(Figs. 5C,D). Furthermore, shotgun proteomic analyses were
performed to determine the protein profile regulated by UBC9 in
cystic cholangiocytes and their potential role in the pathogenesis
of PLD. In total, 3,681 and 3,585 proteins were identified in
controls (non-transfected cystic cholangiocytes and shRNA-
control) and shRNA-UBE2I transfected PHCs, respectively
(Fig. S4A). Among the differentially expressed proteins, 29 pro-
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Fig. 5. Biological effects of UBE2I experimental knockdown in PHCs in vitro. (A) Representative immunoblot and quantification of UBC9 and (B) SUMO1 and
SUMO1-conjugated proteins in shRNA-UBE2I and control (non-transfected and shRNA-control) PHC in culture. (C) Apoptosis (n = 4) and (D) proliferation in
preceding groups (n = 3). (E) Volcano plot of proteins quantified and considered in differential analysis (n = 2,109) by mass spectrometry comparing fold
enrichment in shRNA-UBE2I to controls. Proteomic analyses of the significant dysregulated proteins (n = 120) in the aforementioned groups by (F) gene ontology.
*p <0.05; **p <0.01; ***p <0.001 (one-way ANOVA or Kruskal-Wallis tests). PHCs, polycystic human cholangiocytes; shRNA, short-hairpin RNA.upregulated (dark blue) in shRNA-UBE2I transfected PHCs
compared to controls (Figs. 5E; Fig. S4B; Table S5). Gene ontology
(GO) analysis indicated that the upregulated proteins in shRNA-
UBE2I transfected PHCs are involved in different cellular pro-
cesses including apoptosis (i.e., TRADD, PEA15, PDPK1, PML),
ciliogenesis (i.e., DYNLL2, RAB8, TAGLN2, EHD1), as well as
intracellular transport of proteins (i.e., IPO11, RABGAP1) (Fig. 5F).
Finally, the STRING analysis showed numerous protein-protein
interactions (PPIs) between the identified proteins, with a PPI
enrichment p value of 2.95E-06, indicating that the predicted
functional associations between these proteins are significant
(Fig. S4C).
Most SUMOylated proteins that are elevated in cystic
cholangiocytes are involved in protein biogenesis
To elucidate and compare the SUMOylated proteins in both NHCs
and PHCs, SUMO1-conjugated proteins were isolated by IP and
identified by mass spectrometry (MS). ImmunoblottingJournal of Hepatology 2confirmed enrichment of SUMO1-IP proteins compared to inputs
in respective cell cultures (Fig. 6A). Next, shotgun proteomic an-
alyses identified 67 SUMOylated proteins in NHCs and/or PHCs.
Among them, 26 proteins were differentially expressed between
both cell lines, with increased levels of 22 proteins (85%) and
decreased levels of 4 proteins (15%) in PHCs compared to NHCs
(Fig. 6B; Fig. S5; Table S6). GO analysis pointed out that most of
the SUMOylated proteins found increased in PHCs participate in
biological processes related to actin filament organization (i.e.,
ACTR3, RAN, DBNL), oxidation-reduction process (GLUD1, ASPH,
G6PD), and the protein translation machinery (i.e., RPL7A, RPL17)
(Fig. 6C). The PPI analysis identified different associations pre-
dominantly linked to the protein translational machinery (i.e.,
protein modification, transport, localization and metabolism)
(Fig. 6D). Interestingly, PSMC2, a regulatory subunit of the 26S
proteasome, was found SUMOylated and upregulated in PHCs,
suggesting that the modulation of the proteasome activity might
be a potential mechanism behind the therapeutic effects of SAMe.021 vol. 74 j 394–406 401
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Fig. 6. Comparative SUMOylated protein profile between PHCs and NHCs in culture after SUMO1-immunoprecipitation. (A) Representative immunoblot of
SUMO-IP in NHC and PHC. (B) Volcano plot of all identified SUMO1-IP proteins (n = 67) by mass spectrometry comparing fold enrichment in PHCs to NHCs.
Proteomic analyses of significant identified proteins (n = 26) in aforementioned groups by (C) gene ontology and (D) PPI network. Line color in PPI network
indicates type of interaction evidence. IP, immunoprecipitation; NHCs, normal human cholangiocytes; PHCs, polycystic human cholangiocytes; PPI, protein-
protein interaction.
Research Article Experimental and Translational HepatologySAMe reduces the proteasome activity in cystic
cholangiocytes and induces stress-related apoptosis
Based on the identification of increased PSMC2 SUMOylation
levels in PHCs and the previously described proteasome hyper-
activity of PHCs vs. NHCs4 – together with the baseline increase
of ubiquitinated proteins and p62 (marker of autophagy)
expression in cystic tissue from PLD patients and PCK rats
compared to controls (Fig. S6A–D) – we evaluated the impact of
SAMe on proteasome activity. Interestingly, the chymotrypsin-,
trypsin- and caspase-like proteasome hyperactivities of PHCs
were normalized to baseline NHC values by SAMe administration
(Fig. 7A). Consequently, SAMe induced transcriptional activation
of ubiquitin expression in cystic cholangiocytes (Fig. 7B). None-
theless, this effect was not mirrored by an accumulation of
ubiquitinated proteins in PHCs after SAMe treatment (Fig. S6C,D).
In this regard, several autophagy markers (i.e., SQSTM1/p62, LC3B,
ATG5 and Beclin-1) were overexpressed in cystic cholangiocytes
after SAMe treatment (Fig. 7C), suggesting that autophagy402 Journal of Hepatology 2activation might compensate, at least in part, for the loss of
proteasome degrading capacity. Interestingly, accumulation of
p62 and ubiquitin-conjugated proteins was found in the liver of
SAMe-treated PCK rats (Fig. S6E,F), suggesting the inability of
autophagy to fully compensate for the long-term accumulative
effects of SAMe-driven proteasome inhibition. Next, the effect of
SAMe on the unfolded protein response (UPR) was assessed; we
observed increased expression of the UPR sensors (i.e., ATF6,
IRE1a and PERK) and effectors (i.e., s-XBP1, CHOP and GRP78) on
SAMe-treated cystic cholangiocytes (Fig. 7D). Furthermore,
various stress-related apoptosis markers (i.e., BIM, BAX and DR5)
were likewise elevated in PHCs upon SAMe administration
(Fig. 7F). Notably, the combination of SAMe and MG132, a se-
lective and strong 26S proteasome complex inhibitor, did not
have additive or synergic effect on the apoptosis of PHCs
(Fig. 7G), suggesting a common pathway of apoptosis induction
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Fig. 7. SAMe reduces proteasome activity in cystic cholangiocytes and induces stress-related apoptosis in vitro. (A) Relative proteasome activity of NHCs and
PHCs under baseline conditions or SAMe treatment (n = 4). mRNA levels of (B) ubiquitin (C) autophagy markers (D) UPR sensors and effectors, and (E) apoptosis
markers in the presence/absence of SAMe. (F) Apoptosis (n = 3) in untreated, SAMe-treated, MG132-treated, and combination of SAMe and MG132-treated PHCs.
*p <0.05; **p <0.01; ***p <0.001 (one-way ANOVA or Kruskal-Wallis tests). NHCs, normal human cholangiocytes; PHCs, polycystic human cholangiocytes; SAMe, S-
adenosylmethionine; UPR, unfolded protein response.Discussion
Our data showed that the expression levels of nearly all core
SUMO pathway components are upregulated in both hepatic
cystic tissue and cultured cystic cholangiocytes from humans
and mutant rats with PLD, compared to (corresponding
normal) controls. The relevance of our findings is corroborated
by the presence of increased levels of SUMO1-conjugated
proteins in cystic tissue and cholangiocytes that promote he-
patic cystogenesis in vitro and in vivo. SUMOylation may be
substantially enhanced in response to diverse stimuli, as
illustrated in various conditions such as cancer, certain
neurological conditions, heart failure and diabetes mellitus.5
Earlier reports observed upregulation of SUMO1 and UBC9 in
colorectal cancer and HCC, whereas increased expression of
SAE1/UBA2 was found in HCC.15 Moreover, increased SUMOy-
lation of proteins has been associated with the ER stress-
driven UPR, as it directs the cell into survival or death
depending on the degree of stress.16 Indeed, as a result of the
mutated genes in PLD, misfolded proteins accumulate in theJournal of Hepatology 2ER, thereby inducing prolonged ER stress and subsequently
UPR hyperactivity.4 This suggests that enhanced protein
SUMOylation in PLD could be related with the UPR, driving
disease progression.
Considering the inhibitory capacity of SAMe on the SUMOyla-
tion enzyme UBC9, the homeostasis of this essential endogenous
metabolite was analyzed in detail under baseline conditions in
PLD. SAMe plays a pivotal role in transmethylation, trans-
sulfuration and polyamine biosynthesis, thus impaired SAMe ho-
meostasis may lead to pathological conditions. SAMe is synthe-
sized from methionine by the enzymes MATI and MATIII (gene
productsofMAT1A),whichareprimarilyexpressed in the liver, and
MATII (gene product of MAT2A and MAT2B), which is widely
expressed in extrahepatic tissues.17 Data derived from clinical
studies support the favorable tolerability profile of SAMe supple-
mentation, also improving the serum biochemistries (i.e., AST and
bilirubin) in certain chronic liver conditions.18 The most common
side effect of SAMe is nausea and, less frequently, diarrhea,
abdominal discomfort, or vomiting.19 In view of the excellent021 vol. 74 j 394–406 403
Research Article Experimental and Translational Hepatologysafety profile of SAMe, it is likely that prolonged treatment for a
condition such as PLD will be acceptable. Dysregulated SAMe
homeostasis was observed in PLD, with increased MAT2A and
MAT2B expression (and absence of expression of MAT1A) in both
human and rat cystic cholangiocytes compared to normal chol-
angiocytes. Notably, the administration of SAMe normalized the
protein hyper-SUMOylation levels and upregulated several
markers of biliary and epithelial differentiation in cystic chol-
angiocytes in vitro. Therefore, in order to study the impact of the
protein hyper-SUMOylation state in PLD, SAMewas administrated
to experimental models of PLD in vivo and in vitro. Indeed, chronic
treatment of PCK rats with SAMe (20 mg/kg/day for 5 months)
mitigatedhepatic cystogenesis andfibrosis compared tountreated
PCK controls. Importantly, liver weight, liver/body weight ratio
and liver volume of treated PCK rats were reduced, coupled with
improved serum albumin levels. These therapeutic benefits
mediated by SAMe were associated with the normalization of
SUMO1 and UBC9 protein levels in cystic cholangiocytes (in both
nucleus and cytoplasm), and with pro-apoptotic and anti-
proliferative responses. However, the possibility that other mo-
lecular processesmodulatedbySAMeare involved in the observed
effects cannot be excluded. Interestingly, acute treatment with
higher doses of SAMe in vivo (50 or 100 mg/kg/day for 2 months)
barely led to changes in physical and serum biochemical param-
eters, apart from improvedblood urea values (in the 50mg/kg/day
SAMe group) and improved AST values (in the 100 mg/kg/day
SAMe group) (Fig. S7; Table S7). This implies that SAMe might be
more efficient as a long-term rather than short-term treatment in
PLD. Moreover, oral SAMe treatment was well tolerated and no
adverse effects were noticed in all of the treated PCK groups (i.e.,
20 mg, 50 mg and 100 mg SAMe), corresponding with published
data on SAMe clinical trials.18
UBC9 has a critical role as the single E2 conjugating enzyme
in the multistep pathway of SUMOylation. Since a high propor-
tion of the SUMO substrates appear to be nuclear resident pro-
teins in PLD, alterations in UBC9 expression and activity may
impact numerous cellular processes related to gene transcrip-
tion. To confirm whether the effects of SAMe are due to UBC9
inhibition, as well as to identify potential UBC9 targets by MS,
stable shRNA-UBE2I transfected PHCs were investigated.
Consistent with the results seen in SAMe-treated PHCs, UBE2I
silencing achieved comparable pro-apoptotic and anti-
proliferative effects. Furthermore, proteomic analyses of UBE2I
shRNA-transfected PHCs identified an extensive number (>100)
of differentially expressed proteins, with the majority (~75%)
being upregulated compared to controls. UBE2I silencing in PHCs
elicited functional enrichments of proteins involved in biological
processes such as protein transport, ciliogenesis, and apoptosis.
To identify specific SUMO target proteins, proteomic analyses of
immunoprecipitated SUMO1 proteins were performed. The
number of SUMOylated proteins was increased in PHCs
compared to NHCs. Several biological processes of these
SUMOylated proteins were analogous to the ones found dysre-
gulated under UBE2I silencing in PHC, in particular protein
biogenesis, transport and actin filament organization. On
another note, the abundance of a SUMOylated protein does not
reveal whether its function is altered (i.e., reduced, increased or
unchanged), yet it allows for identification of SUMO targets, such
as PSMC2, a subunit of the 26S proteasome, in which the
SUMOylation status could play an important role in protein
stability and/or function. Interestingly, SAMe was able to404 Journal of Hepatology 2normalize the baseline proteasome hyperactivity in cystic
cholangiocytes; this resulted in transcriptional activation of
ubiquitin, and induction of autophagy markers, UPR and stress-
related apoptosis. Furthermore, combined administration of
SAMe and MG132 did not increment the apoptotic effects exer-
ted by MG132 alone, indicating a shared mechanism of apoptosis
induction for these 2 compounds. This indicates that SUMOyla-
tion of PSMC2 may enhance proteasome stability, promoting the
degradation of un/misfolded proteins, partially alleviating ER
stress and leading to cell survival. Therefore, SAMe administra-
tion, and the consequent PSMC2 de-SUMOylation, could affect
the 26S proteasome conformation and inhibit proteasomal
degradation of proteins, ultimately resulting in increased
apoptosis due to exacerbated stress, as occurs in the MG132-
mediated proteasomal inhibition.17,20 Of note, increased
apoptosis was also observed in UBE2I-silenced PHCs, which
presented an upregulation of various apoptosis-related proteins
(i.e., TRADD, PEA15, PDPK1, PML). The chaperone CDC37 was
found to be downregulated in shRNA-UBE2I cystic chol-
angiocytes; this could affect protein folding, further increase
cellular stress and contribute to enhanced apoptosis. Impor-
tantly, duration and severity of ER stress can determine the
switch between survival and apoptosis.21 Thus, SUMOylation
inhibition may lead to apoptosis in highly stressed cells, whereas
it may favor cell differentiation, polarization and primary cilium
restoration in less-stressed PHCs, suggesting that fine tuning of
stress is crucial for cell fate.
In summary (Fig. 8), this study reveals the important role of
the SUMOylation of proteins in the hepatic cystogenesis of PLD.
Cystic cholangiocytes are characterized by abnormal proteostasis
associated with adaptive PTM mechanisms that promote protein
dynamics. In particular, increased UBC9-dependent SUMOylation
of certain proteins plays a central role in the pathogenesis of PLD,
promoting the activation of pro-survival pathways in cystic
cholangiocytes. Targeting of UBC9 with SAMe halts hepatic cys-
togenesis, thus representing a promising new therapeutic strat-
egy for patients with PLD that deserves clinical evaluation.
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including SUMOylation, resulting in the induction of pro-survival mechanisms
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proliferation and promoting differentiation of cystic cholangiocytes. PTM, post-
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